1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Ocrelizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 100 mg/10 mL
  • 1.3.3 300 mg/10 mL
• 1.4 Market Analysis by Sales Channels
  • 1.4.1 Overview: Global Ocrelizumab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.4.2 Hospital
  • 1.4.3 Retail
  • 1.4.4 Online
• 1.5 Market Analysis by Combination Therapy
  • 1.5.1 Overview: Global Ocrelizumab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.5.2 Obinutuzumab In Combination With Chlorambucil
  • 1.5.3 Obinutuzumab Combined With Bendamustine
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Ocrelizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Relapsing Remitting Multiple Sclerosis (RRMS)
  • 1.6.3 Primary Progressive Multiple Sclerosis (PPMS)
  • 1.6.4 Others
• 1.7 Global Ocrelizumab Market Size & Forecast
  • 1.7.1 Global Ocrelizumab Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Ocrelizumab Sales Quantity (2021-2032)
  • 1.7.3 Global Ocrelizumab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Genentech
  • 2.1.1 Genentech Details
  • 2.1.2 Genentech Major Business
  • 2.1.3 Genentech Ocrelizumab Product and Services
  • 2.1.4 Genentech Ocrelizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Genentech Recent Developments/Updates
• 2.2 F. Hoffmann-La Roche
  • 2.2.1 F. Hoffmann-La Roche Details
  • 2.2.2 F. Hoffmann-La Roche Major Business
  • 2.2.3 F. Hoffmann-La Roche Ocrelizumab Product and Services
  • 2.2.4 F. Hoffmann-La Roche Ocrelizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 F. Hoffmann-La Roche Recent Developments/Updates
• 2.3 Chugai
  • 2.3.1 Chugai Details
  • 2.3.2 Chugai Major Business
  • 2.3.3 Chugai Ocrelizumab Product and Services
  • 2.3.4 Chugai Ocrelizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Chugai Recent Developments/Updates

3 Competitive Environment: Ocrelizumab by Manufacturer

• 3.1 Global Ocrelizumab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Ocrelizumab Revenue by Manufacturer (2021-2026)
• 3.3 Global Ocrelizumab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Ocrelizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Ocrelizumab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Ocrelizumab Manufacturer Market Share in 2025
• 3.5 Ocrelizumab Market: Overall Company Footprint Analysis
  • 3.5.1 Ocrelizumab Market: Region Footprint
  • 3.5.2 Ocrelizumab Market: Company Product Type Footprint
  • 3.5.3 Ocrelizumab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Ocrelizumab Market Size by Region
  • 4.1.1 Global Ocrelizumab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Ocrelizumab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Ocrelizumab Average Price by Region (2021-2032)
• 4.2 North America Ocrelizumab Consumption Value (2021-2032)
• 4.3 Europe Ocrelizumab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Ocrelizumab Consumption Value (2021-2032)
• 4.5 South America Ocrelizumab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Ocrelizumab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Ocrelizumab Sales Quantity by Type (2021-2032)
• 5.2 Global Ocrelizumab Consumption Value by Type (2021-2032)
• 5.3 Global Ocrelizumab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Ocrelizumab Sales Quantity by Application (2021-2032)
• 6.2 Global Ocrelizumab Consumption Value by Application (2021-2032)
• 6.3 Global Ocrelizumab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Ocrelizumab Sales Quantity by Type (2021-2032)
• 7.2 North America Ocrelizumab Sales Quantity by Application (2021-2032)
• 7.3 North America Ocrelizumab Market Size by Country
  • 7.3.1 North America Ocrelizumab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Ocrelizumab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Ocrelizumab Sales Quantity by Type (2021-2032)
• 8.2 Europe Ocrelizumab Sales Quantity by Application (2021-2032)
• 8.3 Europe Ocrelizumab Market Size by Country
  • 8.3.1 Europe Ocrelizumab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Ocrelizumab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Ocrelizumab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Ocrelizumab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Ocrelizumab Market Size by Region
  • 9.3.1 Asia-Pacific Ocrelizumab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Ocrelizumab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Ocrelizumab Sales Quantity by Type (2021-2032)
• 10.2 South America Ocrelizumab Sales Quantity by Application (2021-2032)
• 10.3 South America Ocrelizumab Market Size by Country
  • 10.3.1 South America Ocrelizumab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Ocrelizumab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Ocrelizumab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Ocrelizumab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Ocrelizumab Market Size by Country
  • 11.3.1 Middle East & Africa Ocrelizumab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Ocrelizumab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Ocrelizumab Market Drivers
• 12.2 Ocrelizumab Market Restraints
• 12.3 Ocrelizumab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Ocrelizumab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Ocrelizumab
• 13.3 Ocrelizumab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Ocrelizumab Typical Distributors
• 14.3 Ocrelizumab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Ocrelizumab market size was valued at US$ 1015 million in 2025 and is forecast to a readjusted size of US$ 3388 million by 2032 with a CAGR of 14.6% during review period.
In 2025, global production of Obinutuzumab reached approximately 8.6 million units.Ocrelizumab is a humanized monoclonal antibody primarily used for the treatment of Multiple Sclerosis (MS), including Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS). It works by targeting and inhibiting the activity of B cells, reducing the immune system's attack on the central nervous system, thereby slowing disease progression and reducing relapses. Ocrelizumab is administered via intravenous injection, typically once every six months. The drug has been approved for clinical use in multiple countries and regions, particularly for MS patients who have not responded well to other treatment options.、
Ocrelizumab is a first-line biologic pharmaceutical drug for the treatment of Multiple Sclerosis (MS), and holds an important position in the global market. With the increasing early diagnosis rates of MS, the demand for effective treatments is steadily rising, leading to growing market demand for Ocrelizumab. Particularly in the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS), Ocrelizumab has gradually become a key treatment choice due to its significant efficacy and relatively low side effects.The market prospects for Ocrelizumab are very promising, especially in developed countries and regions, where its excellent efficacy and dosing schedule of once every 6 months greatly improve patient compliance, making it highly favored by both patients and doctors. However, despite its significant therapeutic advantages, the high price of the drug may limit its accessibility in some countries or regions with lower economic conditions.
This report is a detailed and comprehensive analysis for global Ocrelizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Ocrelizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Ocrelizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Ocrelizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Ocrelizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ocrelizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ocrelizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genentech, F. Hoffmann-La Roche, Chugai, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Ocrelizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg/10 mL
300 mg/10 mL
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Combination Therapy
Obinutuzumab In Combination With Chlorambucil
Obinutuzumab Combined With Bendamustine
Market segment by Application
Relapsing Remitting Multiple Sclerosis (RRMS)
Primary Progressive Multiple Sclerosis (PPMS)
Others
Major players covered
Genentech
F. Hoffmann-La Roche
Chugai
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ocrelizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ocrelizumab, with price, sales quantity, revenue, and global market share of Ocrelizumab from 2021 to 2026.
Chapter 3, the Ocrelizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ocrelizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Ocrelizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ocrelizumab.
Chapter 14 and 15, to describe Ocrelizumab sales channel, distributors, customers, research findings and conclusion.